

NORTHAMPTONSHIRE PRESCRIBING ADVISORY GROUP
(Advising Medical, Pharmacy Practitioners and Non-Medical Prescribers
on prescribing across the county)

Summary of Recommendations from meeting on Weds June 29th 2016

- **Enstilar® Cutaneous Foam (Calcipotriol/ betamethasone dipropionate)**

Enstilar is a combination product containing a synthetic vitamin D3 analogue and a synthetic topical corticosteroid (in the same proportions as in Dovobet; 50 micrograms/g + 0.5 mg/g) licensed for topical treatment of psoriasis vulgaris in adults. It is currently the same price as Dovobet and may provide an alternative for patients who are unable to tolerate the ointment formulation.

NPAG categorised Enstilar Cutaneous Foam as green

- **Fluomizin® (dequalinium chloride)**

Dequalinium chloride is an anti-infective and antiseptic agent belonging to the class of quaternary ammonium compounds. Fluomizin vaginal tablets are licensed for the treatment of bacterial vaginosis.

NPAG categorised Fluomizin as green

- **Maculeh Light®**

Maculeh Light is a vitamin and antioxidant product which provides nutritional support in patients with a specific stage of age-related macular degeneration (AMD), following assessment by a consultant ophthalmologist. It is a food supplement with ACBS status.

The evidence for Maculeh Light is based on the AREDS and AREDS2 studies; the same studies as other unlicensed products such as ICaps. Given that there is no new evidence to support the use of this product and that other similar products are double red, **NPAG categorised Maculeh Light as double red (IFR)**

- **Safinamide (Xadogo®)**

Safinamide is a monoamine-oxidase inhibitor B for the treatment of mid- late-stage Parkinson's Disease, with similar efficacy to rasagiline. **NPAG categorised safinamide as grey**, pending further information from the local PD specialists.

- **Alirocumab (Praluent®) and evolocumab (Repatha®)**

Alirocumab and evolocumab are fully human monoclonal antibodies that inhibit proprotein convertase subtilisin / kexin type 9 (PCSK9) and their use is recommended by recent NICE TAs in certain circumstances (see links below).

PCSK9 is a protein that targets Low Density Lipoprotein (LDL) receptors for degradation and thereby reduces the liver's ability to remove LDL-cholesterol from the blood. Evolocumab and alirocumab bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface.

NPAG categorised alirocumab and evolocumab as red

- **Tolvaptan (Samsca® and Jinarc®)**

There are 2 different tolvaptan products available; Samsca for Syndrome of inappropriate ADH secretion (SIADH) and Jinarc for polycystic kidney disease. **NPAG categorised tolvaptan (both products) as red**

- **Mesalazine products**

Due to recent price reductions all mesalazine products, with the exception of Asacol, are now of similar cost. Mezavant XL and Salofalk (tablets and granules) are now additional choices alongside Octasa and Pentasa.

- **Apremilast**

Criteria have been agreed with Nene CCG and with Corby CCG for the use of apremilast in certain patient cohorts and clinical scenarios. **NPAG categorised apremilast as red**

- **Moogoo skin products**

These are cosmetic/toiletry products which can be purchased over-the-counter

NPAG categorised Moogoo skin products as double red

- **Shared care guidance**

These were agreed for prucalopride, linaclotide and ivabradine (angina) and will be available on Pathfinder

- **Policies**

Policies were agreed for Camouflage make up and Free Stock Provision and will be available on Pathfinder

- **NICE Technology Appraisals**

In addition to the NICE TAs for Alirocumab <https://www.nice.org.uk/guidance/TA393> and evolocumab <https://www.nice.org.uk/guidance/ta394> (see above), NPAG noted the sacubitril/valsartan (Entresto®) TA <https://www.nice.org.uk/guidance/ta388> and the timescales relating to implementation.

Further information or clinical trial data may be obtained from the CCG Prescribing Advisers or Hospital Medicines Information Service.

Information in this bulletin is believed to be true and accurate. The NHS and their employees accept no liability for loss of any nature, to persons, organisations or institutions that may arise as a result of any errors or omissions.